Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | not yet recruiting | Phase 4 | 62 | SciClone PharmaceuticalsINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT01995513 | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients(PLATO) | completed | Phase 4 | 509 | PfizerINDUSTRY | 11 | Sep 18, 2023 |
| clinicaltrials |
| NCT06026995 | Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells | unknown | Phase 4 | 174 | Chongqing University Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05235737 | The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab(PIRG) | unknown | Phase 4 | 36 | Medical University of SilesiaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT06010277 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity(FLEX) | unknown | Phase 4 | 50 | Amphia HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT00168727 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma | completed | Phase 4 | 12 | BiogenINDUSTRY | 1 | Aug 23, 2023 | clinicaltrials |
| NCT00314756 | Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage | completed | Phase 4 | 15 | Wake Forest UniversityOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT06001619 | Prostate Medication, Metabolism and Gut Microbiota(PROMED) | recruiting | Phase 4 | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04854018 | Indo-cyanine Green (ICG) in Paediatric Oncology MIS | completed | Phase 4 | 20 | Birmingham Women's and Children's NHS Foundation TrustOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05976893 | Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer | unknown | Phase 4 | 620 | Xiang XieOTHER | 0 | Aug 4, 2023 | clinicaltrials |
| NCT01695863 | Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep | completed | Phase 4 | 150 | Rush University Medical CenterOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05830500 | Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma | recruiting | Phase 4 | 360 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05957653 | Lidocaine Combined With Sufentanil for Preventing Catheter-related Bladder Discomfort | unknown | Phase 4 | 140 | RenJi HospitalOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT01468623 | Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6(PROFUSE) | terminated | Phase 4 | 51 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04591028 | A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT00902720 | Ovarian Tissue Freezing For Fertility Preservation | unknown | Phase 4 | 25 | Oregon Health and Science UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05603065 | Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)(TINES) | unknown | Phase 4 | 32 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01895517 | CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study） | completed | Phase 4 | 18,471 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04381494 | Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.(ON TRAX) | terminated | Phase 4 | 40 | AstraZenecaINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04650204 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy | terminated | Phase 4 | 4 | Mayo ClinicOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT05814848 | A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Phase 4 | 13 | Changhai HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05897749 | Clinical Study on the Effect of Brucea Javanica Oil Emulsion Injection on the Survival of Patients With Advanced Colorectal Cancer Who Failed to Receive Multi-line Treatment | unknown | Phase 4 | 60 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT04769713 | Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures | unknown | Phase 4 | 80 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT04072068 | Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy(EDOI) | completed | Phase 4 | 150 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05606692 | Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)(anesthetics) | recruiting | Phase 4 | 416 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05663242 | The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action | recruiting | Phase 4 | 300 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT03691441 | Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer | unknown | Phase 4 | 280 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05861635 | The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression | unknown | Phase 4 | 42 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05844813 | Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma(NATARS) | enrolling by invitation | Phase 4 | 102 | Peking University International HospitalOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT05844670 | CHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.(CHAPATI) | unknown | Phase 4 | 100 | Moi UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | withdrawn | Phase 4 | 0 | Tokyo Medical and Dental UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients(MM) | withdrawn | Phase 4 | 0 | Al-Rasheed University CollegeOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT03043430 | Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients | terminated | Phase 4 | 10 | Brooke Army Medical CenterFED | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03313544 | Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 | unknown | Phase 4 | 50 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05036005 | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)(NeoON) | unknown | Phase 4 | 108 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05452213 | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients(CAPTOR-BC) | recruiting | Phase 4 | 1,000 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05490953 | Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma | unknown | Phase 4 | 30 | University of GuadalajaraOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05809024 | Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy | unknown | Phase 4 | 100 | Yongsheng WangOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04653818 | HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial(RCT) | completed | Phase 4 | 84 | Alexandria UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05316831 | Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia | completed | Phase 4 | 77 | Region Örebro CountyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05670561 | Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma | unknown | Phase 4 | 60 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT00128297 | Pamidronate Administration in Breast Cancer Patients With Bone Metastases | completed | Phase 4 | 152 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05785208 | Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.(TEMPLE-2) | unknown | Phase 4 | 122 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT00819832 | Anderson Circulating Tumor Cell Burden (CTCB) Study | terminated | Phase 4 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01706120 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab(MITO16/MANGO-2) | unknown | Phase 4 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials